


**CENTER FOR  
CANCER  
RESEARCH**  
 Connecting the Cancer Community


 Innovative Science      Breakthrough Therapies      Clinical Advances

**An ES Cell-Based Functional Assay  
to Study BRCA2 Variants**


**TECH**  
 Council MD

**TEDCO/NIH/NCI Technology Showcase**


**Maryland TEDCO**  
 Technology Development Corporation

**Shyam K. Sharan**  
*September 25, 2007*


**NATIONAL INSTITUTES  
OF HEALTH**  
**NATIONAL  
CANCER  
INSTITUTE**

*Hereditary Breast Cancer:  
BRCA1 & BRCA2*


- Lifetime risk of breast cancer in general population is ~13.2% but *BRCA1* and *BRCA2* carriers have 36-85%
- *BRCA1* consists of 1863 amino acids and *BRCA2* protein has 3418 amino acids
- Mutations are scattered throughout the gene: no hot spots

## *BRCA1 and BRCA2 Mutation Spectrum\**



Mutation Type	Frequency	
	<i>BRCA1</i>	<i>BRCA2</i>
Frame-shift	5805	3436
Single aa change	3559	6168
Nonsense	1309	996
Intronic	1075	438
5' UTR	5	88
In-frame deletion	64	46
In-frame insertion	3	16


\*Source: Breast Cancer Information Core

## *Cancer Predisposing Mutation or Polymorphism?*




- Functional significance of mutations other than frame-shift alterations is unknown
- Lack of suitable functional assay
- Segregation of the disease with the mutation
- Prevalence of the mutation in general population




## Analyzing functional significance of BRCA2 mutations in ES cells



## Human BRCA2 Can Rescue ES cell Lethality




# Y3308X Mutant cells are Viable but Hypersensitive to Genotoxins



# Y3308X cells Exhibit Genomic Instability




Brca2 +/-




Y3308X

# Is E3309X Deleterious or a Polymorphic Variation?



# Scheme to Examine Human Missense Mutations in ES cells



## *Application in Genetic Counseling*



- 10,000 individuals with personal or family history of cancer were screened for *BRCA1* and *BRCA2* mutations by Myriad Genetics\*.
- 5503 indicated a personal history of breast or ovarian cancer
- 17% had deleterious mutations, 13% had one or more variants of unknown clinical significance
- The assay can be used to determine the functional significance of unknown variants

\**Journal of Clinical Oncology* (2002) **20**, 1480-1490.

## *Contact Information*



- ***For further information contact:***

Shyam K. Sharan  
Mouse Cancer Genetics Program  
CCR, NCI-Frederick  
Frederick, MD

Phone: (301) 846-5140  
email: [ssharan@ncifcrf.gov](mailto:ssharan@ncifcrf.gov)